Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Electronic Arts Inc. (EA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Electronic Arts Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.71 (market cap $4.49B), while Electronic Arts Inc. trades at $205.36 (market cap $51.51B). The key difference: Electronic Arts Inc. is far larger — about 11.5× ACADIA Pharmaceuticals Inc.'s market cap, and Electronic Arts Inc. pays a 0.37% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | EA | |
|---|---|---|
Market Cap | $4.49B | $51.51B |
Sector | Health | Technology |
52-Week High | $28.06 | $205.45 |
52-Week Low | $20.06 | $147.79 |
Enterprise Value | $3.69B | $50.08B |
Dividend Yield | — | 0.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Electronic Arts (EA) trades at $205.44, up 0.11% on the day, with a bullish technical signal from moving averages and strong profitability metrics including a 78.97% gross margin. Recent news highlights a potential $55 billion acquisition by Saudi investors pending EU approval and the launch of new gaming titles and an advertising platform, indicating active business development.
The stock presents a mixed outlook with high valuation ratios (P/E of 58.46) posing a risk, but analyst consensus leans positive with no sell ratings. Key risks include earnings volatility, as seen in recent misses, and regulatory scrutiny over the acquisition. Upside potential hinges on successful game launches and the advertising initiative driving future growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Electronic Arts Inc.
EA is one of the world's largest third-party video game publishers and has transitioned from a console-based video game publisher to the one of the largest publishers on consoles, PC, and mobile. The firm owns number of large franchises, including Madden, FIFA, Battlefield, Apex Legends, Mass Effect, Dragon's Age, and Need for Speed.
Read more on EA →
